Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

RDY shares fell approximately 9% after Q1 FY27 results showed a 5.66% year-over-year revenue decline and a 68.7% profit decline. The investigation focuses on investor losses tied to the market reaction to the earnings miss.

July 22, 2026 brought a roughly 9% drop in Dr. Reddy's Laboratories (NYSE: RDY ) shares after the Company reported Q1 FY27 results showing a year-over-year revenue decline and sharply lower profit.

The reported quarter showed revenue down 5.6% year over year and profit down 68.7% year over year. RDY shares fell approximately 9% after the results reached the market.

The investigation is focused on shareholders who suffered losses after RDY's reported earnings miss.

The investigation concerns Dr. Reddy's Laboratories (NYSE: RDY ) and investor losses after the Company reported Q1 FY27 results showing a 5.6% year-over-year revenue decline and a 68.7% year-over-year profit decline. RDY shares fell approximately 9% after the earnings release.

Investors who purchased RDY stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase timing and documented losses -- not on whether you still hold the shares.

RDY shares fell approximately 9% after the Company reported Q1 FY27 results showing lower revenue and sharply lower profit compared with the prior year. The per-share dollar decline was not specified in the materials reviewed.

Investors should gather brokerage records showing purchase dates, share quantities, prices paid, and any sale dates and prices. These records help evaluate losses tied to the market reaction.

Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any later sale dates and prices are the key documents.

Yes. Eligibility is based on when you purchased and whether you suffered losses, not whether you still hold the shares.

Yes. There is no minimum loss amount required to participate in the investigation.

There is no upfront cost to participate. Securities investigations and any resulting proceedings are generally handled on a contingency basis, with no upfront fees, no retainer, and no out-of-pocket costs.